NasdaqGS:MGTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has MeiraGTx Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MGTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: MGTX's weekly volatility (10%) has been stable over the past year.


Market Performance


7 Day Return

-0.4%

MGTX

3.5%

US Biotechs

-1.0%

US Market


1 Year Return

-19.7%

MGTX

36.8%

US Biotechs

19.6%

US Market

Return vs Industry: MGTX underperformed the US Biotechs industry which returned 36.8% over the past year.

Return vs Market: MGTX underperformed the US Market which returned 19.6% over the past year.


Shareholder returns

MGTXIndustryMarket
7 Day-0.4%3.5%-1.0%
30 Day-3.1%4.5%2.2%
90 Day20.8%19.2%11.5%
1 Year-19.7%-19.7%39.0%36.8%22.3%19.6%
3 Yearn/a30.5%23.6%45.3%35.7%
5 Yearn/a43.9%33.0%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is MeiraGTx Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MeiraGTx Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MGTX ($16.36) is trading below our estimate of fair value ($67.7)

Significantly Below Fair Value: MGTX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MGTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MGTX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MGTX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGTX is good value based on its PB Ratio (3.5x) compared to the US Biotechs industry average (4.2x).


Next Steps

Future Growth

How is MeiraGTx Holdings forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

20.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MGTX's revenue (63.4% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: MGTX's revenue (63.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MGTX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MeiraGTx Holdings performed over the past 5 years?

-13.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MGTX is currently unprofitable.

Growing Profit Margin: MGTX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MGTX is unprofitable, and losses have increased over the past 5 years at a rate of 13.1% per year.

Accelerating Growth: Unable to compare MGTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: MGTX has a negative Return on Equity (-29.6%), as it is currently unprofitable.


Next Steps

Financial Health

How is MeiraGTx Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: MGTX's short term assets ($217.9M) exceed its short term liabilities ($46.6M).

Long Term Liabilities: MGTX's short term assets ($217.9M) exceed its long term liabilities ($67.4M).


Debt to Equity History and Analysis

Debt Level: MGTX is debt free.

Reducing Debt: MGTX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MGTX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MGTX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 15.9% each year.


Next Steps

Dividend

What is MeiraGTx Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MGTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MGTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MGTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Alexandria Forbes (55 yo)

5.83yrs

Tenure

US$8,480,263

Compensation

Dr. Alexandria Forbes, Ph.D. serves as the Chief Executive Officer and President at MeiraGTx Holdings plc (formerly known as MeiraGTx Limited) since 2015. Prior to joining MeiraGTx, Dr. Forbes served as Se...


CEO Compensation Analysis

Compensation vs Market: Alexandria's total compensation ($USD8.48M) is above average for companies of similar size in the US market ($USD2.42M).

Compensation vs Earnings: Alexandria's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Alexandria Forbes
CEO, President & Director5.83yrsUS$8.48m3.12%
$ 22.2m
Richard Giroux
COO & CFO1.75yrsUS$7.47m2.15%
$ 15.2m
Robert Wollin
General Counsel & Secretary1.42yrsno datano data
Stuart Naylor
Chief Development Officer5.75yrsUS$2.25m1.01%
$ 7.2m
Gregory Petsko
Chief Scientist & Chairman of Scientific Advisory Boardno datano datano data
Christine Sheehy
Senior Vice President of Global Integrationno datano datano data
Joel Brooks
Senior Vice President of Finance5.67yrsno datano data
Tim Randall
Senior Vice President of Risk & Internal Controls1.75yrsno datano data
Alastair Leighton
Senior Vice President of Manufacturing & Supply Chain2yrsno datano data
Robert Zeldin
Chief Medical Officer0.42yrno datano data

1.9yrs

Average Tenure

57yo

Average Age

Experienced Management: MGTX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Alexandria Forbes
CEO, President & Director5.83yrsUS$8.48m3.12%
$ 22.2m
Gregory Petsko
Chief Scientist & Chairman of Scientific Advisory Boardno datano datano data
Joel Marcus
Independent Director5.58yrsUS$455.13k0.17%
$ 1.2m
Arnold Levine
Member of Scientific Advisory Board & Independent Directorno dataUS$445.13k0%
$ 0
Thomas Shenk
Independent Director & Member of Scientific Advisory Boardno dataUS$440.13k0%
$ 0
Keith Harris
Independent Chairman of the Board2.92yrsUS$498.72k0%
$ 0
Michael Kaplitt
Member of Scientific Advisory Boardno datano datano data
Neil Mendoza
Independent Director5.58yrsUS$455.13k0.030%
$ 210.8k
Ellen Hukkelhoven
Independent Director3.25yrsUS$385.75k0%
$ 0
Martin Indyk
Independent Director1.92yrsUS$524.90k0%
$ 0
James Alwine
Member of Scientific Advisory Boardno datano datano data
Stefano Rivella
Member of Scientific Advisory Boardno datano datano data

4.4yrs

Average Tenure

67.5yo

Average Age

Experienced Board: MGTX's board of directors are considered experienced (4.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.


Top Shareholders

Company Information

MeiraGTx Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MeiraGTx Holdings plc
  • Ticker: MGTX
  • Exchange: NasdaqGS
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$710.223m
  • Shares outstanding: 43.41m
  • Website: https://www.meiragtx.com

Number of Employees


Location

  • MeiraGTx Holdings plc
  • 430 East 29th Street
  • 14th Floor
  • New York
  • New York
  • 10016
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGTXNasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDJun 2018
328DB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2018

Biography

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, includ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 23:59
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.